Compare Moody's Corporation (MCO) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs Nuvalent Inc — how do they compare? Moody's Corporation trades at $490.77 (market cap $88.28B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Moody's Corporation is far larger — about 9× Nuvalent Inc's market cap, and Moody's Corporation pays a 0.82% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| MCO | NUVL | |
|---|---|---|
Market Cap | $88.28B | $9.81B |
Sector | Financials | Technology |
52-Week High | $539.61 | $123.96 |
52-Week Low | $412.23 | $72.16 |
Enterprise Value | $94.08B | $8.52B |
Dividend Yield | 0.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moody's Corporation (MCO) trades at $490.54, down 3.97% in the last session, with strong fundamentals including 31.69% net income margin and 74.54% ROE. The stock shows bullish technical signals with moving averages supporting upward momentum, while recent earnings consistently beat expectations. Revenue growth has accelerated from $5.5B in 2022 to $7.7B in 2025, with Q2 2026 results expected on July 22, 2026.
MCO presents a compelling investment case with premium valuation metrics (P/E 36.25) justified by exceptional profitability and market dominance. Key risks include valuation sensitivity and dependence on debt issuance cycles. Analyst consensus remains bullish with $558.14 price target, representing 13.8% upside potential from current levels.
Nuvalent (NUVL) trades at $123.96, showing no change recently, with technical indicators presenting a mixed signal—moving averages are bullish while oscillators are bearish. The company reported a net loss of $425.38 million for 2025, with negative profitability metrics like ROE of -41.19%. Recent news highlights GSK's proposed acquisition of Nuvalent for $124 per share, totaling $10.6 billion, which is under investigation by multiple law firms for fairness concerns.
The investment outlook is heavily influenced by the pending acquisition, offering a near-term exit at $124 per share. However, risks include ongoing financial losses, negative cash flow from operations, and legal scrutiny over the deal's adequacy. Analyst sentiment is mixed with 42% buy ratings, but the acquisition provides a clear valuation anchor amid fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
